116 related articles for article (PubMed ID: 37666102)
1. Heteroantigen-assembled nanovaccine enhances the polyfunctionality of TILs against tumor growth and metastasis.
Wei L; Zhang Y; Wang R; Liu S; Luo J; Ma Y; Wang H; Liu Y; Chen Y
Biomaterials; 2023 Nov; 302():122297. PubMed ID: 37666102
[TBL] [Abstract][Full Text] [Related]
2. The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma.
Uryvaev A; Passhak M; Hershkovits D; Sabo E; Bar-Sela G
Med Oncol; 2018 Jan; 35(3):25. PubMed ID: 29388007
[TBL] [Abstract][Full Text] [Related]
3. CD4
Lu J; Huang C; He R; Xie R; Li Y; Guo X; Zhang Q; Xu Q
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9007-9016. PubMed ID: 37165118
[TBL] [Abstract][Full Text] [Related]
4. Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8
Gokuldass A; Draghi A; Papp K; Borch TH; Nielsen M; Westergaard MCW; Andersen R; Schina A; Bol KF; Chamberlain CA; Presti M; Met Ö; Harbst K; Lauss M; Soraggi S; Csabai I; Szállási Z; Jönsson G; Svane IM; Donia M
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33198174
[No Abstract] [Full Text] [Related]
5. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.
Dudley ME; Gross CA; Somerville RP; Hong Y; Schaub NP; Rosati SF; White DE; Nathan D; Restifo NP; Steinberg SM; Wunderlich JR; Kammula US; Sherry RM; Yang JC; Phan GQ; Hughes MS; Laurencot CM; Rosenberg SA
J Clin Oncol; 2013 Jun; 31(17):2152-9. PubMed ID: 23650429
[TBL] [Abstract][Full Text] [Related]
6. Bystander CD4
Li S; Zhuang S; Heit A; Koo SL; Tan AC; Chow IT; Kwok WW; Tan IB; Tan DSW; Simoni Y; Newell EW
Oncoimmunology; 2022; 11(1):2012961. PubMed ID: 36524209
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy Shifts the Balance in Favor of CD8+ TNFR2+ TILs in Triple-Negative Breast Tumors.
Baram T; Erlichman N; Dadiani M; Balint-Lahat N; Pavlovski A; Meshel T; Morzaev-Sulzbach D; Gal-Yam EN; Barshack I; Ben-Baruch A
Cells; 2021 Jun; 10(6):. PubMed ID: 34201054
[TBL] [Abstract][Full Text] [Related]
8. The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer.
Wang K; Shen T; Siegal GP; Wei S
Hum Pathol; 2017 Nov; 69():110-117. PubMed ID: 28993275
[TBL] [Abstract][Full Text] [Related]
9. [The regulatory function of tumor-infiltrating Th9 cells to anti-tumor activity of CD8(+) T cells in patients with gastric cancer].
Sun PS; Gao ZJ; Fan LX; Liu YF; Chen BH; Mu SZ; Yan ZQ
Zhonghua Zhong Liu Za Zhi; 2022 Nov; 44(11):1186-1193. PubMed ID: 36380667
[No Abstract] [Full Text] [Related]
10. Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma.
Han S; Zhang C; Li Q; Dong J; Liu Y; Huang Y; Jiang T; Wu A
Br J Cancer; 2014 May; 110(10):2560-8. PubMed ID: 24691423
[TBL] [Abstract][Full Text] [Related]
11. Multifaceted Role of BTLA in the Control of CD8
Ritthipichai K; Haymaker CL; Martinez M; Aschenbrenner A; Yi X; Zhang M; Kale C; Vence LM; Roszik J; Hailemichael Y; Overwijk WW; Varadarajan N; Nurieva R; Radvanyi LG; Hwu P; Bernatchez C
Clin Cancer Res; 2017 Oct; 23(20):6151-6164. PubMed ID: 28754817
[No Abstract] [Full Text] [Related]
12. Human breast tumor-infiltrating CD8
Egelston CA; Avalos C; Tu TY; Simons DL; Jimenez G; Jung JY; Melstrom L; Margolin K; Yim JH; Kruper L; Mortimer J; Lee PP
Nat Commun; 2018 Oct; 9(1):4297. PubMed ID: 30327458
[TBL] [Abstract][Full Text] [Related]
13. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.
Wu R; Forget MA; Chacon J; Bernatchez C; Haymaker C; Chen JQ; Hwu P; Radvanyi LG
Cancer J; 2012; 18(2):160-75. PubMed ID: 22453018
[TBL] [Abstract][Full Text] [Related]
14. Partial purification of murine tumor-associated peptide epitopes common to histologically distinct tumors, melanoma and sarcoma, that are presented by H-2Kb molecules and recognized by CD8+ tumor-infiltrating lymphocytes.
Itoh T; Storkus WJ; Gorelik E; Lotze MT
J Immunol; 1994 Aug; 153(3):1202-15. PubMed ID: 7517974
[TBL] [Abstract][Full Text] [Related]
15. Identification of antigenic epitopes recognized by tumor infiltrating lymphocytes in high grade serous ovarian cancer by multi-omics profiling of the auto-antigen repertoire.
Millar DG; Yang SYC; Sayad A; Zhao Q; Nguyen LT; Warner K; Sangster AG; Nakatsugawa M; Murata K; Wang BX; Shaw P; Clarke B; Bernardini MQ; Pugh T; Thibault P; Hirano N; Perreault C; Ohashi PS
Cancer Immunol Immunother; 2023 Jul; 72(7):2375-2392. PubMed ID: 36943460
[TBL] [Abstract][Full Text] [Related]
16. Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs).
Nguyen LT; Yen PH; Nie J; Liadis N; Ghazarian D; Al-Habeeb A; Easson A; Leong W; Lipa J; McCready D; Reedijk M; Hogg D; Joshua AM; Quirt I; Messner H; Shaw P; Crump M; Sharon E; Ohashi PS
PLoS One; 2010 Nov; 5(11):e13940. PubMed ID: 21085676
[TBL] [Abstract][Full Text] [Related]
17. Theragnostic significance of tumor-infiltrating lymphocytes and Ki67 in BRAFV600-mutant metastatic melanoma (BRIM-3 trial).
Googe PB; Theocharis S; Pergaris A; Li H; Yan Y; McKenna EF; Moschos SJ
Curr Probl Cancer; 2022 Jun; 46(3):100862. PubMed ID: 35398635
[TBL] [Abstract][Full Text] [Related]
18. Functional Heterogeneity of CD4
Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
Front Immunol; 2018; 9():2654. PubMed ID: 30505306
[TBL] [Abstract][Full Text] [Related]
19. Immunologic Characterization and T cell Receptor Repertoires of Expanded Tumor-infiltrating Lymphocytes in Patients with Renal Cell Carcinoma.
Lee MH; Theodoropoulos J; Huuhtanen J; Bhattacharya D; Järvinen P; Tornberg S; Nísen H; Mirtti T; Uski I; Kumari A; Peltonen K; Draghi A; Donia M; Kreutzman A; Mustjoki S
Cancer Res Commun; 2023 Jul; 3(7):1260-1276. PubMed ID: 37484198
[TBL] [Abstract][Full Text] [Related]
20. Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression.
van Houdt IS; Sluijter BJ; Moesbergen LM; Vos WM; de Gruijl TD; Molenkamp BG; van den Eertwegh AJ; Hooijberg E; van Leeuwen PA; Meijer CJ; Oudejans JJ
Int J Cancer; 2008 Aug; 123(3):609-15. PubMed ID: 18498132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
